Doron Ravid, Rozevich Lilach, Bregman-Yemini Noa, Yadid Gal
Department of Education and Psychology, The Open University, Israel.
Health Division, Maccabi Healthcare Services, Tel Aviv, Israel; Neuropharmacology Laboratory, The Mina and Everard Goodman Faculty of Life Sciences, Ramat-Gan, Israel; The Leslie and Susan Gonda (Goldschmied) Multidisciplinary Brain Research Center, Ramat-Gan, Israel.
Eur J Pharmacol. 2025 Jun 5;996:177446. doi: 10.1016/j.ejphar.2025.177446. Epub 2025 Feb 27.
As cocaine dependence becomes highly prevalent among a diverse population, there is a need for innovative treatments that target both the physiological and behavioral aspects of addiction. We have previously published that Dehydroepiandrosterone (DHEA), a neurosteroid, reduces cocaine-seeking behavior and relapse for cocaine use. As drug addiction manifestation is affected by upregulation of β-endorphin levels in the Nucleus Accumbens (NAc), which is vital for the brain's reward system and to the rewarding properties of drugs, the current study aims to determine the effects of DHEA on β-endorphin levels in the NAc and its implications for cocaine addiction treatment.
Utilizing Male Sprague-Dawley rats, DHEA was administered acutely (30 nM and 300 nM) directly into the NAc or as a chronic (14-day) intraperitoneal (i.p.) treatment, and β-endorphin levels were evaluated using microdialysis.
Our results revealed that acute DHEA administration significantly increased β-endorphin levels in the NAc, similar to the response elicited by cocaine. Conversely, chronic DHEA treatment prevents cocaine-induced β-endorphin upregulation in the NAc.
Our findings reveal the dual mechanisms by which DHEA alters β-endorphin levels, highlighting its potential as a therapeutic agent to decrease the rewarding effects of cocaine, by maintaining β-endorphin stability in the NAc. This novel insight may explain the mechanism by which DHEA reduces drug-seeking behavior, suggesting that DHEA may be a viable candidate for the treatment of cocaine addiction.
随着可卡因依赖在不同人群中变得高度普遍,需要有针对成瘾的生理和行为方面的创新治疗方法。我们之前发表过,脱氢表雄酮(DHEA),一种神经甾体,可减少对可卡因的觅药行为和复吸。由于药物成瘾表现受伏隔核(NAc)中β-内啡肽水平上调的影响,而伏隔核对大脑奖励系统和药物的奖赏特性至关重要,当前研究旨在确定DHEA对NAc中β-内啡肽水平的影响及其对可卡因成瘾治疗的意义。
利用雄性斯普拉格-道利大鼠,将DHEA急性(30 nM和300 nM)直接注入NAc或作为慢性(14天)腹腔内(i.p.)治疗给药,并用微透析评估β-内啡肽水平。
我们的结果显示,急性给予DHEA可显著增加NAc中的β-内啡肽水平,类似于可卡因引起的反应。相反,慢性DHEA治疗可防止可卡因诱导的NAc中β-内啡肽上调。
我们的研究结果揭示了DHEA改变β-内啡肽水平的双重机制,突出了其作为一种治疗剂通过维持NAc中β-内啡肽稳定性来降低可卡因奖赏作用的潜力。这一新见解可能解释了DHEA减少觅药行为的机制,表明DHEA可能是治疗可卡因成瘾的一个可行候选药物。